Navigating the mCRPC Landscape: Exploring Key Clinical Decision Points

Summary of presentations from the Bayer-supported satellite symposium, held at the European Association of Urology (EAU) Congress, Madrid, Spain on 22nd March 2015

Chairperson: Fred Saad1
Speakers: Gero Kramer,2 Bertrand Tombal,3 Jürgen Gschwend4

1. University of Montreal, Montreal, Canada
2. Medical University of Vienna, Vienna, Austria
3. Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
4. Rechts der Isar Medical Center, Technical University Munich, Munich, Germany

Disclosure: Professor Saad has received advisory board and/or research funding from Abbott, Amgen, Astellas, Bayer, Janssen, Millennium, Novartis, and Sanofi. Professor Kramer has received scientific  advisory board/honoraria from Sanofi, Bayer, Janssen, Takeda, Astellas, Ipsen, and Pfizer. Professor  Tombal has acted as an investigator for Astellas, Bayer, Ferring, Janssen, Medivation, Sanofi, and Takeda, and as a paid consultant or speaker for Amgen, Astellas, Bayer, Ferring, Medivation, Sanofi, and Takeda. Professor Gschwend has received honoraria from Amgen, Astellas, Bayer, Janssen, Novartis, and PierreFabre, and advisory board fees from Amgen, Astellas, Bayer, BMS, Janssen, Novartis, Pfizer, Pierre-Fabre, Roche, and Teva.
Acknowledgements: Writing assistance was provided by Dr Saroshi Amirthalingam, apothecom scopemedical Ltd.
Support: The publication of this article was funded by Bayer. The views and opinions expressed are those  of the authors and not necessarily of Bayer.
Citation: EMJ Urol 2015;3[2]:57–62.

Meeting Summary

The Bayer satellite symposium was introduced by Prof Fred Saad, who gave an introduction into the use of radium-223 in metastatic castration-resistant prostate cancer (mCRPC). Results from the recent Phase III ALpharadin in SYMptomatic Prostate Cancer (ALSYMPCA) study were also presented. Profs  Kramer, Tombal, and Gschwend then each presented case studies on patients they had treated with radium-223. Each speaker also provided their own personal view and recommendations for use of  radium-223 based on their experience with these patients. Prof Gschwend concluded the symposium  with important considerations for the urologist in using radium-223 in mCRPC.

Download (PDF, 93KB)

Comments are closed.